- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01366144
Veliparib, paklitaxel a karboplatina při léčbě pacientů se solidními nádory, které jsou metastázující nebo je nelze odstranit chirurgicky, a dysfunkce jater nebo ledvin
Studie časné fáze 1 ABT-888 v kombinaci s karboplatinou a paklitaxelem u pacientů s jaterní nebo renální dysfunkcí a solidními nádory
This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver or kidney dysfunction. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with paclitaxel and carboplatin may kill more tumor cells.
Přehled studie
Postavení
Podmínky
Detailní popis
PRIMARY OBJECTIVES:
I. To determine the pharmacokinetics and pharmacodynamics of ABT-888 (veliparib) in patients with varying degrees of renal or hepatic dysfunction.
II. To determine the maximum tolerated dose (MTD) of ABT-888 in combination with carboplatin and paclitaxel for patients with varying degrees of liver or kidney dysfunction.
III. To provide dosing recommendations for ABT-888 in combination with carboplatin and paclitaxel based on degree of hepatic and renal impairment.
SECONDARY OBJECTIVES:
I. To define the dose-limiting toxicity (DLT) and other toxicities associated with the use of this combination in patients with varying degrees of renal or hepatic dysfunction.
II. To evaluate the pharmacokinetic parameters of ABT-888, carboplatin, and paclitaxel when administered as a combination in patients with varying degrees of renal or hepatic dysfunction.
III. To evaluate the pharmacodynamic measurement of poly-ADP-ribosylated (PAR) and platinum adducts in tumor cells associated with the use of this combination in patients with varying degrees of renal or hepatic dysfunction.
OUTLINE: This is a dose-escalation study of veliparib.
Patients receive veliparib* orally (PO) twice daily (BID) on days 1-7 and paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30 minutes on day 3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
NOTE: * All patients receive a single dose of veliparib PO on day -6 before course 1 (except patients with very severe renal dysfunction who receive veliparib on day -5 or -6 to coincide with a dialysis day).
After completion of study treatment, patients are followed up for 4 weeks.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
California
-
Duarte, California, Spojené státy, 91010
- City of Hope Comprehensive Cancer Center
-
Sacramento, California, Spojené státy, 95817
- University of California Davis Comprehensive Cancer Center
-
South Pasadena, California, Spojené státy, 91030
- City of Hope South Pasadena
-
-
Florida
-
Tampa, Florida, Spojené státy, 33612
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30322
- Emory University Hospital/Winship Cancer Institute
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Detroit, Michigan, Spojené státy, 48201
- Wayne State University/Karmanos Cancer Institute
-
-
New Jersey
-
New Brunswick, New Jersey, Spojené státy, 08903
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
New York, New York, Spojené státy, 10065
- Memorial Sloan Kettering Cancer Center
-
The Bronx, New York, Spojené státy, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Spojené státy, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
Ohio
-
Cleveland, Ohio, Spojené státy, 44106
- Case Western Reserve University
-
-
Pennsylvania
-
Hershey, Pennsylvania, Spojené státy, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Pittsburgh, Pennsylvania, Spojené státy, 15232
- UPMC Hillman Cancer Center
-
-
Texas
-
Houston, Texas, Spojené státy, 77030
- UT MD Anderson Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, Spojené státy, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Patients must have histologically confirmed malignancy that is radiologically evaluable and metastatic or unresectable, for which standard curative or palliative measures do not exist or are no longer effective, and for which there is expectation of response to the combination of carboplatin/paclitaxel (i.e., lung, ovarian, breast, melanoma, head and neck, endometrial, urothelial, testicular, esophageal, carcinoma of unknown primary); for indications not listed, eligibility based on disease must be verified by the principal investigator before they are considered
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Life expectancy of greater than 12 weeks
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 100,000/mcL
- Hemoglobin >= 8.0 g/dL
- Patients with all degrees of renal dysfunction are allowed including patients on hemodialysis; patients with mild to severe hepatic dysfunction are allowed as defined below:
- Total bilirubin =< 5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 10 x ULN
- For patients with a recently placed biliary stent, patients should have consistent results within a hepatic group from two laboratory readings within 3 days apart, taken at least 10 days following biliary stent placement; for patients with a biliary stent placed over 2 months ago, no obstruction or blockage can have occurred within the last 2 months
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those whose adverse event due to agents administered more than 4 weeks earlier have not resolved or stabilized; patients who have been administered ABT-888 as part of a single or combination, phase 0 or I study, should not necessarily be excluded from participating in this study solely because of receiving prior ABT-888
- Patients may not be receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study
- Peripheral neuropathy of severity greater than grade 1
- Inability to take oral medications on a continuous basis
- Evidence of bleeding diathesis
- Patients with central nervous system (CNS) metastases must be stable after therapy for CNS metastases (such as surgery, radiotherapy or stereotactic radiosurgery) for at least 3 months and must be off steroid treatment prior to study enrollment
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888; these potential risks may also apply to other agents used in this study
- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV-positive patients without an acquired immune deficiency syndrome (AIDS)-defining diagnosis who are not receiving agents with the potential for pharmacokinetic (PK) interactions with ABT-888 may be eligible
- Patients with both hepatic and renal dysfunction will also be excluded
- Patients who received and progressed on the combination of carboplatin/paclitaxel will not be eligible
- Active seizure or history of seizure disorder
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Treatment (veliparib, paclitaxel, carboplatin)
Patients receive veliparib* PO BID on days 1-7 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 3. Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. NOTE: * All patients receive a single dose of veliparib PO on day -6 before course 1 (except patients with very severe renal dysfunction who receive veliparib on day -5 or -6 to coincide with a dialysis day). |
Given IV
Ostatní jména:
Given IV
Ostatní jména:
Correlative studies Given PO
Ostatní jména:
Correlative studies |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
MTD veliparibu v kombinaci s karboplatinou a paklitaxelem, stanoveno podle incidence DLT, jak je odstupňováno pomocí Common Terminology Criteria for Adverse Events (NCI CTCAE) Národního institutu pro rakovinu, verze (v) 4.0
Časové okno: 21 dní
|
21 dní
|
|
|
PK parameters of veliparib
Časové okno: Day -6 and 3 of course 1 after veliparib dosing
|
Standard quantitative and graphical statistical summaries of the derived PK parameters (e.g. area under curve and clearance) will be produced for each organ function cohort. The effect of dysfunction on pharmacokinetics will be explored by comparing each pharmacokinetic parameter across all cohorts using one-way analysis (analysis of variance) or Kruskal-Wallis test. The level of each protein will be compared between responders and non-responders using the Wilcoxon signed rank test. |
Day -6 and 3 of course 1 after veliparib dosing
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Incidence of toxicities as assessed by NCI CTCAE v4.0
Časové okno: Up to 4 weeks after completion of study treatment
|
The maximum grade of toxicity for each category of interest will be recorded for each patient and the summary results will be tabulated by category, grade and dose level. Severe and life-threatening toxicities and adverse event-related deaths (>= grade 3) will be described on a patient-by-patient basis and will include any relevant baseline data. |
Up to 4 weeks after completion of study treatment
|
|
Response rate as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Časové okno: Up to 4 weeks after completion of study treatment
|
Responses will be tabulated by disease diagnosis and by dose level. 95% confidence limits will also be reported on the response rates. |
Up to 4 weeks after completion of study treatment
|
|
Incidence of stable disease as assessed by RECIST version 1.1
Časové okno: Up to 4 weeks after completion of study treatment
|
Incidence of stable disease will be tabulated by disease diagnosis and by dose level. |
Up to 4 weeks after completion of study treatment
|
|
Time to progression
Časové okno: Up to 4 weeks after completion of study treatment
|
Displayed for all patients and for patients who have responded; no formal statistical analysis is planned. |
Up to 4 weeks after completion of study treatment
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in PAR levels
Časové okno: Baseline to up to 4 weeks
|
Descriptive statistics (mean, standard deviation, median, range) for measurements of PAR levels will provided with 95% confidence intervals (CIs). When sample size permits, a formal statistical test using the Wilcoxon signed rank test will be used to compare the post treatment PAR levels to the baseline levels. When feasible, the level will be compared between responders and non-responders using the Wilcoxon signed rank test. |
Baseline to up to 4 weeks
|
|
Change in gamma-H2AX levels
Časové okno: Baseline to up to 4 weeks
|
Descriptive statistics (mean, standard deviation, median, range) for measurements of gamma-H2AX levels will provided with 95% CIs. When sample size permits, a formal statistical test using the Wilcoxon signed rank test will be used to compare the post treatment PAR levels to the baseline levels. When feasible, the level will be compared between responders and non-responders using the Wilcoxon signed rank test. |
Baseline to up to 4 weeks
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Hussein A Tawbi, University of Pittsburgh Cancer Institute (UPCI)
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhadovaný)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Urogenitální onemocnění
- Onemocnění genitálií
- Onemocnění endokrinního systému
- Patologické procesy
- Genitální novotvary, muži
- Urogenitální novotvary
- Novotvary podle místa
- Novotvary
- Onemocnění pohlavních orgánů, muž
- Mužská urogenitální onemocnění
- Onemocnění ledvin
- Urologická onemocnění
- Ženské urogenitální onemocnění
- Ženské urogenitální onemocnění a těhotenské komplikace
- Nemoci dýchacích cest
- Novotvary podle histologického typu
- Gastrointestinální novotvary
- Novotvary trávicího systému
- Nemoci trávicího systému
- Gastrointestinální onemocnění
- Onemocnění dělohy
- Onemocnění pohlavních orgánů, ženy
- Plicní onemocnění
- Novotvary endokrinních žláz
- Onemocnění jater
- Novotvary, žlázové a epiteliální
- Novotvary dýchacího traktu
- Novotvary hrudníku
- Neoplastické procesy
- Nemoci jícnu
- Onemocnění vaječníků
- Adnexální onemocnění
- Genitální novotvary, ženy
- Gonadální poruchy
- Kožní choroby
- Nemoci prsu
- Karcinom
- Neuroektodermální nádory
- Novotvary, zárodečné buňky a embryonální
- Novotvary, nervová tkáň
- Novotvary dělohy
- Neuroendokrinní nádory
- Nevi a melanomy
- Novotvary kůže
- Jaterní nedostatečnost
- Testikulární nemoci
- Patologické stavy, příznaky a symptomy
- Onemocnění kůže a pojivové tkáně
- Novotvary plic
- Novotvary jícnu
- Novotvary vaječníků
- Novotvary prsu
- Metastáza novotvaru
- Novotvary hlavy a krku
- Melanom
- Novotvary endometria
- Renální insuficience
- Karcinom, přechodná buňka
- Selhání jater
- Novotvary, neznámé primární
- Testikulární novotvary
- Organické chemikálie
- Uhlovodíky
- Cykloparafiny
- Uhlovodíky, alicyklické
- Uhlovodíky, cyklické
- Terpeny
- Koordinační komplexy
- Taxoidy
- Cyclodecanes
- Diterpeny
- Ekonomika a organizace zdravotní péče
- Ekonomika
- Karboplatina
- Paklitaxel
- Veliparib
- Daně
Další identifikační čísla studie
- NCI-2011-02500
- U01CA070095 (Grant/smlouva NIH USA)
- UM1CA186691 (Grant/smlouva NIH USA)
- UM1CA186716 (Grant/smlouva NIH USA)
- U01CA099168 (Grant/smlouva NIH USA)
- U01CA062502 (Grant/smlouva NIH USA)
- U01CA062505 (Grant/smlouva NIH USA)
- U01CA062490 (Grant/smlouva NIH USA)
- U01CA069856 (Grant/smlouva NIH USA)
- UM1CA186690 (Grant/smlouva NIH USA)
- UM1CA186717 (Grant/smlouva NIH USA)
- UM1CA186709 (Grant/smlouva NIH USA)
- N01CM00100 (Grant/smlouva NIH USA)
- P30CA047904 (Grant/smlouva NIH USA)
- NCI-2011-02500 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
- CDR0000700997
- UPCI 10-115
- UPCI-10-115
- 8808 (Jiný identifikátor: CTEP)
- 8808 (Jiný identifikátor: UPMC Hillman Cancer Center)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .